1h Free Analyst Time
The viral vectors market is poised to grow by $490.64 mn during 2022-2026, accelerating at a CAGR of 14.23% during the forecast period. The report on the viral vectors market provides a holistic analysis, market size and forecast, trends, growth drivers, challenges, and vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of chronic diseases, increasing use of viral vectors to develop gene therapies and vaccines and growing funding for and investments in gene therapies and vaccines.
The viral vectors market analysis includes the application segment and geographic landscape.
The viral vectors market is segmented as below:
By Application
- Gene therapy
- Vaccines
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the viral vectors market covers the following areas:
- Viral vectors market sizing
- Viral vectors market forecast
- Viral vectors market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Application
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global viral vectors market: Batavia Biosciences BV, Bayer AG, Catalent Inc., Creative Biogene, Danaher Corp., F. Hoffmann La Roche Ltd., FinVector Oy, Freeline Therapeutics Holdings plc, FUJIFILM Holdings Corp, Institut Merieux, Lonza Group Ltd., Merck KGaA, Novartis AG, Oxford Biomedica Plc, REGENXBIO Inc, Sirion Biotech GmbH, Takara Holdings Inc, Thermo Fisher Scientific Inc., uniQure NV, and Virovek Inc.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is increasing number of r and d activities for the development of gene therapies and vaccines using viral vectors.`
According to the report, one of the major drivers for this market is the rising prevalence of chronic diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Batavia Biosciences BV
- Bayer AG
- Catalent Inc.
- Creative Biogene
- Danaher Corp.
- F. Hoffmann La Roche Ltd.
- FinVector Oy
- Freeline Therapeutics Holdings plc
- FUJIFILM Holdings Corp
- Institut Merieux
- Lonza Group Ltd.
- Merck KGaA
- Novartis AG
- Oxford Biomedica Plc
- REGENXBIO Inc
- Sirion Biotech GmbH
- Takara Holdings Inc
- Thermo Fisher Scientific Inc.
- uniQure NV
- Virovek Inc
